Neurocrine Biosciences, Inc. has grown revenue 26% a year over three years and 27% a year over five, with earnings per share compounding at 58%. Revenue growth, 3-year annual rate: +26% (Drug Manufacturers - Specialty & Generic median +13%). Revenue growth, 5-year rate: +27%, growth has slowed since the five-year average. Earnings per share, 3-year rate: +58%, earnings outgrew revenue: margins or the share count worked for shareholders. Years of annual history on file: 17, FY2009 to FY2025, as filed.

NBIXNeurocrine Biosciences, Inc.

Healthcare

$142.40-1.9% 1Y

$142.40

$123.1052 weeks$182.85

Is it growing?

Excellent

Growing: revenue growing +34% year on year, earnings up +102% year on year, and operating margin widening (+4.6 points).

3 good

Revenue trend+34% in a year

Trailing-twelve-month revenue vs a year earlier, from the company's own filings. Five-year pace: +27% a year.

Earnings trend+102% in a year

Trailing-twelve-month earnings per share against a year earlier. Growing faster than revenue, so margins or the share count are helping.

Margin direction+4.6 points operating

Trailing-twelve-month operating margin, 23.9% now against 19.4% a year earlier.

All from SEC EDGAR, as of Jun 30, 2026.

Against the whole market›

Percentile against every name Ryufin tracks. Higher is better; the tick marks the middle of the market. Context, not one of the checks above.

Revenue growth, 3 yearstop 8% of the market

Where this answer is blind. These are trailing numbers from the filings, not forecasts: an acquisition or a one-off year can flatter them, so check the quarters.

Is NBIX growing?

Neurocrine Biosciences, Inc. has grown revenue 26% a year over three years and 27% a year over five, with earnings per share compounding at 58%.

+26%

Revenue growth, 3-year annual rate · Drug Manufacturers - Specialty & Generic median +13% · compounding fast · compounded from trailing twelve-month revenue

Revenue growth, 5-year rate: +27%
Revenue growth, 5-year rate · +26% over three · growth has slowed since the five-year average
Earnings per share, 3-year rate: +58%
Earnings per share, 3-year rate · revenue +26% · earnings outgrew revenue: margins or the share count worked for shareholders
Years of annual history on file: 17
Years of annual history on file · FY2009 to FY2025, as filed